Primary cutaneous peripheral T-cell lymphoma, not otherwise specified with mammalian target of rapamycin mutation: A novel finding for targeted treatment

Carlo De la Sancha; Callie Burgin; Simon Warren; Kristin Hoffmann; Utpal Davé; Mehdi Nassiri

doi:10.1016/j.jdcr.2020.08.041

Primary cutaneous peripheral T-cell lymphoma, not otherwise specified with mammalian target of rapamycin mutation: A novel finding for targeted treatment

JAAD Case Rep. 2020 Sep 14;6(12):1342-1344. doi: 10.1016/j.jdcr.2020.08.041. eCollection 2020 Dec.

Authors

Carlo De la Sancha¹, Callie Burgin², Simon Warren¹, Kristin Hoffmann², Utpal Davé², Mehdi Nassiri¹

Affiliations

¹ Department of Pathology and Laboratory Medicine, Indiana University School of Medicine, Indianapolis, Indiana.
² Department of Dermatology, Indiana University School of Medicine, Indianapolis, Indiana.

No abstract available

Keywords: BCL6 corepressor; BCL6 corepressor loss; CD20; CD30– T-cell lymphoma; CD30– cutaneous T-cell lymphoma; CD30– lymphoma; T-cell lymphoma; TAK-228; cutaneous T-cell lymphoma, cutaneous T-cell lymphoma, not otherwise specified; mTOR, mammalian target of rapamycin; mammalian target of rapamycin; mammalian target of rapamycin inhibitor; mammalian target of rapamycin mutation; pcPTCL-NOS, primary cutaneous peripheral T-cell lymphoma, not otherwise specified; peripheral T-cell lymphoma; peripheral T-cell lymphoma, not otherwise specified; peripheral T-cell lymphoma, unspecified; primary cutaneous lymphoma; primary cutaneous peripheral T cell lymphoma, not otherwise specified; primary cutaneous peripheral T-cell lymphoma; rituximab.

Publication types

Case Reports

Publication types

Grants and funding